SCHEMBL2884131

SCHEMBL2884131

CC(C)(C)S(=O)(=O)N[C@H]1CC[C@H](c2nc3ccc(-c4ccccc4)cc3[nH]2)CC1

nearest known ligand 0.49

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
NPY5R Q15761 3/20 0.49
USP30 Q70CQ3 5/20 0.48
HTR2B P41595 5/20 0.47
USP2 O75604 1/20 0.41
ABL1 P00519 1/20 0.41
TRPV1 Q8NER1 1/20 0.41
MEN1 O00255 1/20 0.41
ALDH1A1 P00352 1/20 0.41
LMNA P02545 1/20 0.41
MAPT P10636 1/20 0.41
HTT P42858 1/20 0.41
KMT2A Q03164 1/20 0.41
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
ROCK2 O75116 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2884125 0.92 HTR2B (0.47) NPY5RUSP30HTR2BROCK2
SCHEMBL2884128 0.92 HTR2B (0.47) NPY5RUSP30HTR2BROCK2
SCHEMBL2884212 0.88 NPY5R (0.52) NPY5RUSP30HTR2BMEN1ALDH1A1
SCHEMBL2879397 0.88 NPY5R (0.52) NPY5RUSP30HTR2BMEN1ALDH1A1
SCHEMBL2884909 0.83 MAPT (0.49) NPY5RUSP30HTR2BUSP2MEN1
SCHEMBL2885187 0.83 MAPT (0.49) NPY5RUSP30HTR2BUSP2MEN1
SCHEMBL2886433 0.82 NPY5R (0.48) NPY5RUSP30HTR2BLMNAMAPT
SCHEMBL2884299 0.82 NPY5R (0.48) NPY5RTRPV1ALDH1A1LMNAMAPT
SCHEMBL2882317 0.82 HTR2B (0.44) NPY5RUSP30HTR2BUSP2ROCK2
SCHEMBL2884373 0.82 NPY5R (0.54) NPY5RUSP30HTR2BTRPV1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7691860-B2 Sulfonamide derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2010-04-06 US claimed
US-20080161326-A1 Novel Sulfone Amide Amide Derivatives MSD K.K. (JP) 2008-07-03 US claimed
EP-1719765-A1 NOVEL SULFONE AMIDE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2006-11-08 EP claimed
US-7691860-B2 Sulfonamide derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2010-04-06 US disclosed
US-20080161326-A1 Novel Sulfone Amide Amide Derivatives MSD K.K. (JP) 2008-07-03 US disclosed
EP-1719765-A1 NOVEL SULFONE AMIDE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2006-11-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080161326-A1 Novel Sulfone Amide Amide Derivatives NPY1R, NPY2R, NPY5R NPY5R 3/4885USP30 3878/4885HTR2B 112/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.